raxibacumab

REMS

Treatment of inhalational anthrax in combination with anti-infective agents.
Prevention of inhalational anthrax when other agents cannot be used or are unavailable.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

None.

Use Cautiously in:

OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: pruritus, rash

MS: extremity pain

Neuro: drowsiness

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), infusion reactions

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection: 50 mg/mL

Route/Dosage ⬆ ⬇

IV (Adults and Children > 40 kg): 40 mg/kg as a single dose.
IV (Children >10–40 kg): 60 mg/kg as a single dose.
IV (Children ≤10 kg): 80 mg/kg as a single dose.

Action ⬆ ⬇

A monoclonal antitoxin that blocks the activity of toxin produced by Bacillus anthracis. The toxin is a primary cause of disease progression.

Therapeutic effects:

Decreased morbidity and mortality associated with inhalational anthrax exposure and disease.

Classifications ⬆ ⬇

Therapeutic Classification: antidotes

Pharmacologic Classification: monoclonal anti-toxins

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Some tissue distribution.

Metabolism/Excretion: No renal clearance.

Half-Life: 20.4 days

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	end of infusion	unknown

Patient/Family Teaching ⬆ ⬇

Explain purpose of raxibacumab to patient or parents.
Advise patient to notify health care professional immediately if rash, hives, itching, swelling of the mouth, or difficulty breathing occur during or after infusion. Advise that diphenhydramine may delay signs of hypersensitivity.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Rep: Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

49401- GlaxoSmithKline LLC
- 49401-080-
  - 49401-080-92- 7 kg in 1 BAG (49401-080-92)

71655- Emergent Manufacturing Operations Baltimore LLC
- 71655-103- Raxibacumab
  - 71655-103-01- 1 VIAL, SINGLE-USE in 1 CARTON (71655-103-01) / 34 mL in 1 VIAL, SINGLE-USE

section name header

Indications ⬇